60 likes | 172 Views
FISH for CLL for CRC. Dr. Gordon Dewald Dr. Constance Griffin Dr. Maria Dell'Aquia Dr. Paola Dal Cin Dr. Kimberly Hayes Dr. Nyla Heerema Dr. Carlo Croce Dr. Andrew Greaves Dr. Tom Kipps. Teleconference Participants. Kimberly Hayes MDA khayes@mdanderson.org Nyla Heerema
E N D
FISH for CLL for CRC Dr. Gordon Dewald Dr. Constance Griffin Dr. Maria Dell'Aquia Dr. Paola Dal Cin Dr. Kimberly Hayes Dr. Nyla Heerema Dr. Carlo Croce Dr. Andrew Greaves Dr. Tom Kipps
Teleconference Participants Kimberly Hayes MDA khayes@mdanderson.org Nyla Heerema OSU Cytogentics heerema-1@medctr.osu.edu Carlo Croce Thomas Jefferson University c_croce@lac.tju.edu Andrew W. Greaves Biomedical Informatics CLL Research Consortium UCSD- agreaves@ucsd.edu Gordon Dewald Mayo Clinic gdewald@mayo.edu Constance Griffin John Hopkins University Cancer Center cgriffin@jhmi.edu Maria Dell'Aquia UCSD Cytogenetics mdellaquila@ucsd.edu Dr. Paola Dal Cin Dana Farber Cancer Center pdalcin@partners.org
Big picture • Goal of teleconference: Agree or not to agree to work together to perform FISH for CLL for the CRC • If we agree, lets develop an outline of work for the next couple years or so. • Write a proposal by early March to include in the upcoming CRC renewal due in June. • Budget discussions: Who pays for all this?
Preliminary thoughts about FISH in CLL for the CRC • Standardize FISH studies for CRC • Phase I: Survey of particpants to learn about available equipment, experience, probes, procedures etc. Followed by a teleconference to compare results and look for ways to improve • Phase II: Perform a pilot study involving 5 to 10 known specimens. Followed by a teleconference to compare results and look for problems. • Phase III: Profiency test involving 20 or 30 specimens. Followed by a teleconference to compare results. Could result in a publication and a critical time point to begin collecting FISH results for the CRC. • Phase IV: Annual proficiency test to assure continued standard FISH testing for CRC. • Application of FISH to special research studies. • Use FISH studies with CRC clinical trials to help assess efficacy of treatment. • Compare FISH results with other prognostic factors in CLL e.g. CD38, IgHv mutation status, ZAP70, conventional cytogenetics and others as they are developed. • Develop new probes for potential loci that could increase the efficacy of FISH in cliniical practice. • Search for the “holy grail” of CLL by working with Dr. Croce and others. • Who keeps the FISH data? • Local cytogenetic laboratory • CRC data base center • Both local and database center
What is next? • Can we work together? • Write first draft of grant proposal • Thoughts about budget • When do we start?